New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/
[Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive
In recent years, the use of high-frequency wireless communication in the automotive sector has increased. It is primarily used for content distribution for navigation, audio and other infotainment systems. Improving sensitivity and noise suppression in these advanced high-frequency communication systems becomes mission critical to support the connected car for ADAS (Advanced Driver Assistance Systems) and eventually autonomous driving.
RF inductors typically used for noise suppression in sub-6GHz communication have a narrow frequency band at high impedance, making it necessary to select components that match the noise frequency band. With its broad high-frequency band at high impedance, the BLM15VM series allows easy noise suppression across multiple frequency bands using just one product. Even at 5.9GHz, the chip ferrite beads within the series will typically attain impedance values of 1000Ω.
By enabling error-free high-frequency communication, which is crucial for autonomous driving, the BLM15VM series significantly improves reception sensitivity in V2X communication in the 5.9GHz bands for autonomous driving and stable operation of dedicated short-range communication (DSRC) based control systems, operating in the 5.8GHz band, for improved road safety. Additionally, since Wi-Fi 6E and Wi-Fi 7, the communication standards for wireless LAN, also use the sub-6GHz band, this product can improve sensitivity and suppress noise in consumer communication devices.
The AEC-Q200-compliant BLM15VM series of chip ferrite beads from Murata supports operating temperatures between -55 to 150°C and is supplied in a compact 0402-inch size (1.0×0.5mm). Murata is committed to expanding its lineup to meet market needs.
For more details about the Product, see the ‘BLM15VM150BH1’ page.
Requests of free small-quantity samples are available here.
For inquiries regarding the product, click here.
Editor’s Notes
According to the Company's research. This is the world's first product that removes noise in high-frequency communication (including Sub6 bands) for C-V2X, as of June 18, 2025.
About Murata
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618511573/en/
Contacts
For more information, please contact:
Murata Manufacturing Co., Ltd.
Keisuke Tsuboi, prsec_mmc@murata.com
Corporate Communications Department
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom